SRRK Stock Overview A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Scholar Rock Holding Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Scholar Rock Holding Historical stock prices Current Share Price US$41.53 52 Week High US$46.19 52 Week Low US$6.76 Beta 0.53 1 Month Change -3.13% 3 Month Change 41.98% 1 Year Change 166.39% 3 Year Change 124.73% 5 Year Change 307.96% Change since IPO 167.94%
Recent News & Updates
Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High Dec 24
Price target increased by 15% to US$42.88 Nov 25 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 10
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 09
Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million. Oct 08
Price target increased by 11% to US$29.75 Oct 07 See more updates
Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High Dec 24
Price target increased by 15% to US$42.88 Nov 25 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 10
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million. Oct 09
Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million. Oct 08
Price target increased by 11% to US$29.75 Oct 07
Scholar Rock: SMA Program Strides Forward With Positive Clinical Data Oct 07
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy Oct 07
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer Sep 04
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt? Aug 13
New major risk - Financial position Aug 09
Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal Jun 24
CFO, COO & Treasurer recently sold US$85k worth of stock Jun 20
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting May 29
Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024 May 01
New major risk - Shareholder dilution Apr 19
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt? Apr 15
Price target increased by 8.1% to US$26.25 Mar 28
New minor risk - Share price stability Mar 21
New major risk - Financial position Mar 19
President recently sold US$183k worth of stock Feb 22
Scholar Rock Announces Management Appointments Feb 15
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management Feb 06
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity Jan 23
Scholar Rock: Solid Data And Good Prospects Jan 12
CFO, COO & Treasurer notifies of intention to sell stock Jan 01
Senior VP & Head of Research recently sold US$295k worth of stock Dec 17
CFO, COO & Treasurer notifies of intention to sell stock Dec 10
Price target increased by 7.1% to US$25.71 Dec 08
New major risk - Revenue and earnings growth Nov 08
CFO, COO & Treasurer notifies of intention to sell stock Nov 05
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability Nov 04
Price target increased by 9.8% to US$24.00 Oct 26
Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting Oct 20 Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million. Oct 13
Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial Sep 20
Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab Jul 01
Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023 May 04
Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up Apr 19
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Mar 09
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer Feb 07
Price target decreased to US$22.57 Nov 19
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021) Nov 16
Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy Nov 11
Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer Nov 10
Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA Oct 23
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy Oct 20 Scholar Rock Announces Chief Executive Officer Changes
Jay Backstrom is the new CEO at Scholar Rock Sep 20
Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021) Aug 10
Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors Jul 27
Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology Jul 12 Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index
Price target decreased to US$29.00 Jun 23
Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment Jun 18
Consensus revenue estimates increase by 75% May 25
Consensus revenue estimates increase by 75% May 23
Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts May 21
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 17 Scholar Rock Holding Corporation Provides Pipeline Updates
Price target decreased to US$44.67 Apr 27
Price target decreased to US$46.17 Mar 23
Consensus forecasts updated Mar 14
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 09
Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher Mar 08
Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022 Jan 12
Price target decreased to US$55.80 Dec 24
Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Dec 01
CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock Nov 17
Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020) Nov 11
Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress Sep 24
Consensus forecasts updated Aug 19
Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020) Aug 12
Board Member notifies of intention to sell stock Jul 31
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress Jun 19
Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting Jun 12
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting Jun 08
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy May 25
Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting May 21
Forecast to breakeven in 2025 May 19
First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020) May 16
Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be May 15
Consensus revenue estimates fall to US$22.8m May 15
Price target decreased to US$64.00 May 15 Shareholder Returns SRRK US Biotechs US Market 7D 1.7% -3.6% -1.2% 1Y 166.4% -8.4% 23.2%
See full shareholder returns
Return vs Market: SRRK exceeded the US Market which returned 21.6% over the past year.
Price Volatility Is SRRK's price volatile compared to industry and market? SRRK volatility SRRK Average Weekly Movement 11.0% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 19.0% 10% least volatile stocks in US Market 3.2%
Stable Share Price: SRRK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SRRK's weekly volatility has decreased from 52% to 11% over the past year.
About the Company Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Show more Scholar Rock Holding Corporation Fundamentals Summary How do Scholar Rock Holding's earnings and revenue compare to its market cap? SRRK fundamental statistics Market cap US$3.89b Earnings (TTM ) -US$225.97m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SRRK income statement (TTM ) Revenue US$0 Cost of Revenue US$169.15m Gross Profit -US$169.15m Other Expenses US$56.82m Earnings -US$225.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.41 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 63.3%
How did SRRK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/15 08:31 End of Day Share Price 2025/01/14 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Scholar Rock Holding Corporation is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Etzer Darout BMO Capital Markets Equity Research Guyn Kim BMO Capital Markets Equity Research
Show 13 more analysts 
